Intensity Therapeutics (INTS) Convertible Debt (2022)
Intensity Therapeutics' (INTS) quarterly Convertible Debt came in at $4.3 million in Q4 2022.
Intensity Therapeutics (INTS) Convertible Debt (2022) Analysis & Trends
Intensity Therapeutics (INTS) has 1 years of Convertible Debt data on file, last reported at $4.3 million in Q4 2022.
- Quarterly Convertible Debt changed N/A year-over-year to $4.3 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $4.3 million (changed N/A YoY) and the FY2022 annual result came in at $4.3 million, changed N/A from the prior year.
- Convertible Debt held at $4.3 million in Q4 2022.
- In the past five years, Convertible Debt ranged from a high of $4.3 million in Q4 2022 to a low of $4.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Intensity Therapeutics | 13.06 Mn | 13.06 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 4.35 Mn |